Literature DB >> 15105423

Positive and negative determinants of target gene specificity in myb transcription factors.

Wanli Lei1, John J Rushton, Lisa M Davis, Fan Liu, Scott A Ness.   

Abstract

The A-Myb and c-Myb transcription factors share a highly conserved DNA-binding domain and activate the same promoters in reporter gene assays. However, the two proteins have distinct biological activities, and expressing them individually in human cells leads to the activation of distinct sets of endogenous genes, suggesting that each protein has a unique transcriptional specificity. Here, the structural and functional features of the Myb proteins were compared, using assays of endogenous gene expression to measure changes in specificity. When the Myb proteins were tested in different cell types, they activated unique and nearly nonoverlapping sets of genes in each cellular context. Deletion and domain swap experiments identified small, discreet positive and negative elements in A-Myb and c-Myb that were required for the regulation of specific genes, such as DHRS2, DSIPI, and mim-1. The results suggest that individual functional elements in the transcriptional activation domains are responsible for activating specific cellular genes in a context-specific manner. The results also have important implications for interpreting results from reporter gene assays, which fail to detect the differences in activity identified through endogenous gene assays, and fusion protein constructs that alter the transcriptional activation domains and the activities of the Myb proteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105423     DOI: 10.1074/jbc.M403133200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas.

Authors:  Ruth G Tatevossian; Bo Tang; James Dalton; Tim Forshew; Andrew R Lawson; Jing Ma; Geoff Neale; Sheila A Shurtleff; Simon Bailey; Amar Gajjar; Suzanne J Baker; Denise Sheer; David W Ellison
Journal:  Acta Neuropathol       Date:  2010-11-03       Impact factor: 17.088

2.  The Myb-p300 Interaction Is a Novel Molecular Pharmacologic Target.

Authors:  Xi Liu; Kathryn A Gold; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2015-05-20       Impact factor: 6.261

3.  Editorial: Targeting MYB Oncogene Expression in Adenoid Cystic Carcinoma.

Authors:  Scott A Ness
Journal:  J Natl Cancer Inst       Date:  2017-09-01       Impact factor: 13.506

Review 4.  Pleiotropic functions of EAPII/TTRAP/TDP2: cancer development, chemoresistance and beyond.

Authors:  Chunyang Li; Shi-Yong Sun; Fadlo R Khuri; Runzhao Li
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

5.  Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53.

Authors:  Chad Deisenroth; Aaron R Thorner; Takeharu Enomoto; Charles M Perou; Yanping Zhang
Journal:  Mol Cell Biol       Date:  2010-06-14       Impact factor: 4.272

6.  Positive and negative regulation of c-Myb by cyclin D1, cyclin-dependent kinases, and p27 Kip1.

Authors:  Wanli Lei; Fan Liu; Scott A Ness
Journal:  Blood       Date:  2005-02-01       Impact factor: 22.113

7.  Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer.

Authors:  Aaron R Thorner; Joel S Parker; Katherine A Hoadley; Charles M Perou
Journal:  PLoS One       Date:  2010-10-07       Impact factor: 3.240

8.  Multifarious transcriptional regulation of adhesion protein gene ap65-1 by a novel Myb1 protein in the protozoan parasite Trichomonas vaginalis.

Authors:  Shiou-Jeng Ong; Hong-Ming Hsu; Hsing-Wei Liu; Chien-Hsin Chu; Jung-Hsiang Tai
Journal:  Eukaryot Cell       Date:  2006-02

9.  Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma.

Authors:  Kathryn J Brayer; Candace A Frerich; Huining Kang; Scott A Ness
Journal:  Cancer Discov       Date:  2015-12-02       Impact factor: 39.397

10.  RFX2 is a candidate downstream amplifier of A-MYB regulation in mouse spermatogenesis.

Authors:  Gary C Horvath; Malathi K Kistler; W Stephen Kistler
Journal:  BMC Dev Biol       Date:  2009-12-09       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.